{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:49:37Z","timestamp":1791312577158,"version":"4.3.1"},"reference-count":30,"publisher":"EDP Sciences","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1051\/medsci\/2008241105","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T14:54:43Z","timestamp":1299164083000},"page":"105-110","source":"Crossref","is-referenced-by-count":24,"title":["OPG\/RANKL"],"prefix":"10.1051","volume":"24","author":[{"given":"Pierre","family":"Marie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2008,1,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Marie PJ. Diff\u00e9renciation, fonction et r\u00e9gulation de l\u2019ost\u00e9oblaste.Med Sci (Paris)2001; 12 : 1252\u20139.","DOI":"10.1051\/medsci\/200117121252"},{"key":"R2","unstructured":"Marie P, Debiais F, Cohen-Solal M, de Vernejoul MC. De nouveaux facteurs contr\u00f4lent le remodelage osseux.Rev Rhumatol2000; 67 : 260\u20137."},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Suda T, Takahashi N, Udagawa N,et al.Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.Endocr Rev1999; 20 : 345\u201357.","DOI":"10.1210\/er.20.3.345"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.J Mol Med2001; 79 : 243\u201353.","DOI":"10.1007\/s001090100226"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation.Nature2003; 423 : 337\u201342.","DOI":"10.1038\/nature01658"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.Immunol Rev2005; 208 : 30\u201349.","DOI":"10.1111\/j.0105-2896.2005.00327.x"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease.Trends Mol Med2006; 12 : 17\u201325.","DOI":"10.1016\/j.molmed.2005.11.007"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Huang JC, Sakata T, Pfelger LL,et al.PTH differentially regulates expression of RANKL and OPG.J Bone Miner Res2004; 19 : 235\u201344.","DOI":"10.1359\/JBMR.0301226"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Spencer GJ, Utting JC, Etheridge SL,et al.Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesisin vitro. J Cell Sci2006; 119 : 1283\u201396.","DOI":"10.1242\/jcs.02883"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Holmen SL, Zylstra CR, Mukherjee A,et al.Essential role of beta-catenin in postnatal bone acquisition.J Biol Chem2005; 280 : 21162\u20138.","DOI":"10.1074\/jbc.M501900200"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Kostenuik PJ, Shaloub V. Osteoprotegerin : a physiological and pharmacological inhibitor of bone resorption.Curr Pharm Des2001; 7 : 613\u201335.","DOI":"10.2174\/1381612013397807"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.Curr Opin Pharmacol2005; 5 : 618\u201325.","DOI":"10.1016\/j.coph.2005.06.005"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases.JAMA2004; 292 : 490\u20135.","DOI":"10.1001\/jama.292.4.490"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Seeman E, Delmas P. Bone quality-the material and structural basis of bone strength and fragility.N Engl J Med2006; 354 : 2250\u201361.","DOI":"10.1056\/NEJMra053077"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis.Endocrinol Metab Clin North Am2005; 34 : 1015\u201330.","DOI":"10.1016\/j.ecl.2005.07.009"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Rodan GA, Martin TJ. Therapeutic approaches to bone diseases.Science2000; 289 : 1508\u201314.","DOI":"10.1126\/science.289.5484.1508"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Nakamichi Y, Udagawa N, Kobayashi Y,et al.Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.J Immunol2007; 178 : 192\u2013200.","DOI":"10.4049\/jimmunol.178.1.192"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Eghbali-Fatourechi G, Khosla S, Sanyal A,et al.Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.J Clin Invest2003; 111 : 1221\u201330.","DOI":"10.1172\/JCI17215"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Martin TJ. Current, new and emerging anti-resorptive drugs; antibody blockade of RANKL action.BoneKey-Osteovision2006; 3 : 42\u20136.","DOI":"10.1138\/20060214"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Riggs BL, Parfitt AM. Drugs used to treat osteoporosis : the critical need for a uniform nomenclature based on their action on bone remodeling.J Bone Miner Res2005; 20 : 177\u201384.7.","DOI":"10.1359\/JBMR.041114"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Hofbauer LC, Khosla S, Dunstan CR,et al.Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.Endocrinology1999; 140 : 4367\u201370.","DOI":"10.1210\/en.140.9.4367"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.Exp Mol Med2002; 34 : 145\u201351.","DOI":"10.1038\/emm.2002.21"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.J Cell Biochem2003; 89 : 180\u201390.","DOI":"10.1002\/jcb.10490"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Bolon B, Carter C, Daris M,et al.Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.Mol Ther2001; 3 : 197\u2013205.","DOI":"10.1006\/mthe.2001.0245"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Bekker PJ, Holloway D, Nakanishi A,et al.The effect of a single dose of osteoprotegerin in postmenopausal women.J Bone Miner Res2001; 16 : 348\u201360.","DOI":"10.1359\/jbmr.2001.16.2.348"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"McClung MR, Lewieki EM, Cohen SB,et al.Denosumab in postmenopausal women with low bone mineral density.N Engl J Med2006; 354 : 821\u201331.","DOI":"10.1056\/NEJMc060819"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Marie PJ. Strontium ranelate : a dual mode of action rebalancing bone turnover in favour of bone formation.Curr Opin Rheumatol2006; 18 : S11\u20135.","DOI":"10.1097\/01.bor.0000229522.89546.7b"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Meunier PJ, Roux C, Seeman E,et al.The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.N Engl J Med2004; 350 : 459\u201368.","DOI":"10.1056\/NEJMoa022436"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Reginster JY, Seeman E, De Vernejoul MC,et al.Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis : treatment of peripheral osteoporosis (TROPOS) study.J Clin Endocrinol Metab2005; 90 : 2816\u201322.","DOI":"10.1210\/jc.2004-1774"},{"key":"R30","unstructured":"Brennan T, Rybchyn MS, Conigrave AD, Mason RS. Strontium ranelate effect on proliferation and OPG expression in osteoblasts.Calcif Tissue Int2006; 78 : S1\u2013129."}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2008241105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T23:53:15Z","timestamp":1560037995000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2008241105"}},"subtitle":["Implication et cible th\u00e9rapeutique dans l\u2019ost\u00e9oporose"],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":30,"journal-issue":{"issue":"1"},"alternative-id":["medsci2008241p105"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/2008241105","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}